Highlights Zymeworks Inc.

Equities

ZYME

US98985Y1082

Real-time Estimate Cboe BZX Other stock markets 01:31:32 2024-05-01 pm EDT			5-day change	1st Jan Change
8.58 ^USD	0.00%		+0.64%	-17.18%

Apr. 08	Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting	CI
Apr. 04	Zymeworks Inc. Removes Christopher Astle from the Positions of Chief Financial Officer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting	Apr. 08	CI
Zymeworks Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Zymeworks Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
Zymeworks Inc. to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting	Mar. 05	CI
Zymeworks Appoints Jeffrey Smith as Chief Medical Officer; Cash Runway Extended	Jan. 04	MT
Zymeworks Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Zymeworks Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers	23-06-02	CI
Zymeworks Inc. Enters into License and Collaboration Agreement with Jazz Pharmaceuticals Ireland Limited	23-05-16	CI
Zymeworks Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Zymeworks Inc. Announces New Data from its Clinical and Preclinical Development-Stage Programs at the 2023 American Association for Cancer Research Annual Meeting	23-04-18	CI
Zymeworks Terminates Research, Development, Commercialization Agreement with Daiichi Sankyo	23-03-20	MT
Zymeworks Posts Q4 Profit As Revenue Jumps; Shares Rise After-Hours	23-03-07	MT
Zymeworks Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-07	CI
Earnings Flash (ZYME) ZYMEWORKS Reports Q4 EPS $4.71	23-03-07	MT
Zymeworks Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-07	CI
Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Phase 2 Trial Evaluating Zanidatamab in Her2-Expressing Metastatic Gastroesophageal Adenocarcinoma	23-01-19	CI
Zymeworks Updates on Cash Resources; Chief Medical Officer to Depart Amid Internal Reorganization	23-01-04	MT
Jazz Pharmaceuticals plc and Zymeworks Announce Jazz Has Confirmed Opt-In and Advances Partnership for Zanidatamab	22-12-21	CI
Zymeworks Brief: Announcing "Positive" Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab	22-12-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Zymeworks Inc.

Equities

ZYME

US98985Y1082

Highlights

Filters